@article{6bb9e24ee12f47f98bb47939f6bc0719,
title = "Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI",
abstract = "Background: Retinal atrophy in multiple sclerosis (MS) as measured by optical coherence tomography (OCT) correlates with demyelinating lesions and brain atrophy, but its relationship with cortical lesions (CLs) and meningeal inflammation is not well known. Objectives: To evaluate the relationship of retinal layer atrophy with leptomeningeal enhancement (LME) and CLs in MS as visualized on 7 Tesla (7T) magnetic resonance imaging (MRI). Methods: Forty participants with MS underwent 7T MRI of the brain and OCT. Partial correlation and mixed-effects regression evaluated relationships between MRI and OCT findings. Results: All participants had CLs and 32 (80%) participants had LME on post-contrast MRI. Ganglion cell/inner plexiform layer (GCIPL) thickness correlated with total CL volume (r =−0.45, p < 0.01). Participants with LME at baseline had thinner macular retinal nerve fiber layer (mRNFL; p = 0.01) and GCIPL (p < 0.01). Atrophy in various retinal layers was faster in those with certain patterns of LME. For example, mRNFL declined –1.113 (–1.974, –0.252) μm/year faster in those with spread/fill-pattern LME foci at baseline compared with those without (p = 0.01). Conclusion: This study associates MRI findings of LME and cortical pathology with thinning of retinal layers as measured by OCT, suggesting a common link between meningeal inflammation, CLs, and retinal atrophy in MS.",
keywords = "7 Tesla, MRI, leptomeningeal enhancement, meningeal inflammation, multiple sclerosis, optical coherence tomography, retinal atrophy",
author = "Ryan Mizell and Hegang Chen and Jeffrey Lambe and Shiv Saidha and Harrison, {Daniel M.}",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for data acquisition for this study was provided by NIH/NINDS (1K23NS072366-01A1 and 1R01NS104403-01; to D.M.H.) and EMD-Serono (to D.M.H.). Time for data analysis was also supported by Race to Erase MS (to S.S.), Genentech (to S.S.), and National MS Society (RG-1606-08768 to S.S.). Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.M., H.C., and J.L. have no disclosures. S.S. has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Genzyme, Genentech Corporation, EMD-Serono & Celgene. He is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen Idec, received support from the Race to Erase MS foundation, and was the site investigator of a trial sponsored by MedDay Pharmaceuticals. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. D.M.H. has received consulting fees from Genentech, EMD-Serono, Biogen, and Sanofi-Genzyme. He has received research support from EMD-Serono and Genentech. He has received royalties and writing fees for UpToDate, Inc. and the American College of Physicians. Funding Information: The authors wish to thank the OCT technicians at Johns Hopkins and the University of Maryland and the MRI technologists at the Kennedy Krieger Institute for their assistance in obtaining the data used in this study. They also wish to thank their research nurses and research coordinators for their tireless work in organizing and implementing study visits. They also thank members of Dr Harrison{\textquoteright}s laboratory, including Seongjin Choi, PhD, for assistance with image processing. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for data acquisition for this study was provided by NIH/NINDS (1K23NS072366-01A1 and 1R01NS104403-01; to D.M.H.) and EMD-Serono (to D.M.H.). Time for data analysis was also supported by Race to Erase MS (to S.S.), Genentech (to S.S.), and National MS Society (RG-1606-08768 to S.S.). Publisher Copyright: {\textcopyright} The Author(s), 2021.",
year = "2022",
month = mar,
doi = "10.1177/13524585211023343",
language = "English (US)",
volume = "28",
pages = "393--405",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",
}